Ascendis Pharma A/S (ASND) is a publicly traded company in the Healthcare — Biotechnology industry listed on NASDAQ. This overview shows the latest price, key valuation ratios, profitability metrics and financial-health indicators used by fundamental investors.
Ascendis Pharma A/S is a biopharmaceutical enterprise dedicated to advancing therapeutic solutions for critical medical conditions that currently lack effective treatments. Its commercialized offering is SKYTROFA, a therapy prescribed for individuals suffering from growth hormone deficiency (GHD). The company boasts a robust development pipeline, featuring several TransCon-branded candidates.
Is Ascendis Pharma A/S stock overvalued or undervalued in 2026?
Ascendis Pharma A/S (ASND) trades at 18.5× earnings (P/E). No valuation verdict: it has no earnings to calculate a P/E from.
Kaplio overview: Ascendis Pharma A/S
Market cap $16B · 52 weeks $196 – $277 (10 % below the high) · P/E 18.5× · 2027 est. P/E 24.6× · Dividend none · Next earnings November 11, 2026 · expected EPS $0.91 · Closing price, Nov 3 · accounts published Aug 13.
- Valuation: P/Sales 18.6× (no earnings).
- Balance sheet: Grey zone (watch).
- Earnings: 5 of 8 (uneven).
What would it be worth at its usual multiples?
No valuation verdict: it has no earnings to calculate a P/E from.
What matters in biotech: 1 of 4 pass
- R&D / Market cap 1.9 %, fails.
- Market cap / Cash 24.6×, fails.
- Total Debt 1.5×, borderline.
- Annual cash burn $0.85, passes.
Against its peers (reference peers) — Ascendis Pharma A/S: P/E 18.5×; EV/EBITDA 183×; ROIC 5.8 %; $16.5B. Neurocrine Biosciences, Inc. (P/E 24.5×; EV/EBITDA 15.3×; ROIC 14.3 %; $16.8B), BioMarin Pharmaceutical Inc. (P/E —; EV/EBITDA 31.9×; ROIC -1.0 %; $10.8B), United Therapeutics Corporation (P/E 21.5×; EV/EBITDA 14.2×; ROIC 17.7 %; $25.8B).
Investor methods verdict
Would Buffett approve Ascendis Pharma A/S today?
The Buffett Method would not approve Ascendis Pharma A/S today: it fails its quality rules. Business quality: 20 out of 100 (price not included). Kaplio assessment with data from the week of November 2, 2026; not investment advice.
Would Peter Lynch approve Ascendis Pharma A/S today?
The Lynch Method would not approve Ascendis Pharma A/S today: it fails its quality rules. Business quality: 0 out of 100 (price not included). Lynch classifies it as a stalwart. Kaplio assessment with data from the week of November 2, 2026; not investment advice.
Profitability
| Return on Equity | 190.44% |
| Return on Invested Capital | 5.80% |
| Return on Assets | 33.08% |
| Gross Margin | 90.19% |
| Operating Margin | 10.38% |
| Net Margin | 71.69% |
Financial Health
| Debt / Equity | 0.31 |
| Current Ratio | 2.99 |
| Piotroski F-Score | 5 |
| Altman Z-Score | 1.84 |
Price Performance
| 1 month | +9.19% |
| 3 months | -0.35% |
| Year-to-date | +16.76% |
| 1 year | +19.56% |
| 3 years | +163.05% |
| 5 years | +54.95% |
| 10 years | +1193.40% |
Related companies: INSM · UTHR · NBIX · BMRN · CORT · MBX · SEPN
Explore sector: Healthcare · Biotechnology
More sections of ASND: Financials · Valuation · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Companies that pass the Buffett method · Companies that pass the Lynch method · Stocks that pass Graham's defensive investor test today · Investment Academy — learn to analyze stocks